RELIEF THERAPEUTICS Holding SA Announces an Out-Licensing Agreement with H&H Group
RELIEF THERAPEUTICS Holding SA (“Relief”, “the Company”) announces that it has concluded a licensing and co-development agreement (the “Agreement”) with Health and Happiness (H&H) Hong Kong Limited (“H&H”), part of H&H Group to develop products which are derived from whey and/or no-fat milk and have the potential to prevent allergies. The Agreement will follow a four-year development plan including pre-clinical and clinical milestones with the goal of reducing allergenicity or even preventing food (particularly milk) allergy in humans. The product(s) under development are based on the technology discovered by the French company Genclis SA (“Genclis”) that has established the role and consequences of Transcription Infidelity (TI) on allergy. This series of discoveries are the basis for their patent application referred to as the Molecular Origin of Allergy (WO 2017/158202) on which Relief has acquired in April 2018 a license for the development and commercialization of hypoallergenic milk produced without hydrolysis.
The global allergy market that includes diagnostic and therapeutic, is currently growing at a 5.5% CAGR per year and is estimated to reach $42.8 billion by 2022 (Grand View Research, January 2016).
The Agreement includes upfront and milestone payments as well as royalties on any products generated via the collaboration that, as contractually agreed, are distributed across the entire duration of the program. In addition, H&H will fund development to be conducted at Genclis as well as at H&H premises. Details of the overall financial contribution are not disclosed.
Patrice Malard, Chief Technology Officer of H&H declares: “The H&H group ambitions to become a global leader in advanced baby nutrition and care, this Agreement is an important step for our company to reach and serve in a disruptive manner this current $6 billion-hypoallergenic milk infant market. We have been positively impressed by the potential of the technology developed at Genclis and we are excited to work with both Relief and Genclis to translate this technology into novel commercial products.”
Bernard Bihain, Chief Executive Officer of Genclis adds: “We are thrilled to take part in this ambitious program relying on a disruptive basic science finding to obtain industrial application that will greatly benefit the general health and can provide powerful innovative solution for children of allergic parents.”
Gaël Hédou, Chief Executive Officer of Relief concludes by saying: “We are pleased to see that Relief could convey to H&H our appreciation of the groundbreaking and disruptive nature of Genclis’ discoveries. Given the fluidity and speed of the interaction that we experienced during the course of the discussions between the different stakeholders to reach this Agreement, we are confident that this collaboration will be efficient and rapidly productive”
Health and Happiness (H&H) Hong Kong Limited is a subsidiary of Health and Happiness (H&H) International Holdings Limited which is listed on the Main Board of the Stock Exchange of Hong Kong and part of H&H Group. H&H Group was established in 1999, it operates through two core business segments - Baby Nutrition and Care and Adult Nutrition and Care. The Baby Nutrition and Care segment engages in production of infant formulas for children under seven years old and milk formulas for expectant and nursing mothers, production of probiotic supplements, and production of baby care products. The Adult Nutrition and Care Products segment is engaged in the production of vitamins, health supplements, skin care and sports nutrition products for adults. H&H Group currently owns four international brands: Biostime ® : global leader in premium infant nutrition; Swisse ®: Australia’s leading natural health brand; Healthy Times ®: a favorite organic baby food brand in the US since 1980’s; Dodie ®: French heritage brand since 1957 in baby bottles and accessories. H&H Group is a premium nutrition and wellness provider for the entire family, it aspires to make people healthier and happier.
About Relief Therapeutics Holding SA
RELIEF THERAPEUTICS Holding AG is a clinical-stage biotechnology company with a portfolio of drug candidates derived from natural human origins. Its two first candidates are Aviptadil for the treatment of sarcoidosis (to enter Phase III) and low dose interleukin-6 (Atexakin alfa) for the treatment of peripheral neuropathy (to enter Phase II). Aviptadil development in sarcoidosis addresses the orphan disease market, in which European regulators have indicated that a single pivotal Phase III trial would be sufficient to support approval. Atexakin alfa is the subject of an exclusive worldwide development and commercialization agreement with Merck KGaA, The current priority indication for Atexakin is to alleviate peripheral diabetic neuropathy, a market that is estimated to reach $4.1 billion in 2019 (source Datamonitor). In addition to these initial drug candidates, Relief has initiate a strategic collaboration with Genclis in April 2018 in order to co-develop and commercialize products arising from their disruptive technology.
About Genclis SA
Genclis is a privately-held biotechnology company incorporated in 2004 in Vandœuvre-lès-Nancy, France, that discovered a unique biological mechanism referred to as Transcription Infidelity (TI). TI produces RNA transcripts that differ from their originating DNA sequence. This mechanism explains the nonrandom occurrence of RNA to DNA divergences (RDD) that lead to translated proteins with sequences diverging from the canonical form. Genclis applies its artificial intelligence platform to extract, from large Genomic data sets, these low-intensity signals. Genclis has shown in both humans and animal models that specific RDD events shape selectively the repertoire of natural immunoglobulins and contribute to both allergy and other immunological disorders. Genclis has developed a diversified pipeline of disruptive diagnostic and therapeutic solutions that have and are completing pre-clinical evaluation. Genclis revenues grew >500 % to €2.2 million in fiscal year 2017 missing breakeven by less than 10 %. Genclis’ objectives for 2018 are to further expand commercial activities in both human and veterinary medicine as well as in the food industry to reach profitability, while relentlessly pursuing developments of several other novel disruptive pre-clinical assets.
About Transcription Infidelity
Transcription Infidelity (TI) is a newly discovered ubiquitous epigenetic mechanism that increases RNA-DNA sequence divergences (RDD). TI was initially described and patented by Genclis1 and has since been confirmed by several independent academic teams2. TI can lead to base substitutions, insertions and deletions. The latter cause translational frameshifts that have important consequences in determining protein immunogenicity3. Genclis currently focuses on defining the effects of TI proteins translated from gapped RNA on normal and pathological humoral immunity.
Brulliard et al., 2007. PNAS, 104 (18): 7522–27 and
“Transcription Infidelity, detection and uses thereof”, EP2046986,
2 Ju et al., 2011. Nature Genetics 43 (8): 745–52; Li et al., 2011. Science, 333 (6038): 53–58; Peng et al., 2012. Nat Biotechnol 30: 253–60, Reid-Bayliss and Loeb, 2017. PNAS 114 (35): 9415.
3 Genclis patent: “Molecular origin of allergy“, EP16305297, WO2017158202A1.
RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and is headquartered in Geneva, Switzerland.
For further information, please visit the Relief website at www.relieftherapeutics.com
Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning Relief Therapeutics Holding SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Relief Therapeutics Holding SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Relief Therapeutics Holding SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
RELIEF THERAPEUTICS Holding SA
Dr. Gael Hédou
tel: +41 79 457 0937
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Warm welcome for ABB Formula E in Davos19.1.2019 09:00 | Pressemelding
Just a few days before the start of the World Economic Forum 2019, Davos is celebrating a world premiere: The latest ABB FIA Formula E racing car - dubbed Gen2 – was transported on a train from the iconic Swiss Rhaetian Railway to Europe’s highest city, where it will be an exciting eyecatcher during the coming week at the Davos Platz railway station. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190119005003/en/ ABB FIA Formula E racing car in Davos (Photo: Business Wire) From this Saturday until next Sunday, January 27, the Gen2 will be on display in a special glass case. Interested passersby can learn about the ABB FIA Formula E racing series as well as about the activities of ABB in e-mobility via an information system. With over 8,500 fast charging stations installed in 70 countries around the world, ABB is the global market leader for charging infrastructures. To watch the video, click here ABB (ABBN: SIX Swiss Ex) is
PMI’s Mission Winnow Goes Full Throttle with Ducati Corse for 2019 MotoGP™18.1.2019 17:00 | Pressemelding
Philip Morris International Inc. (PMI) (NYSE: PM) is pleased to announce that its Mission Winnow initiative is expanding in 2019 to include the Ducati Corse racing team. Mission Winnow is a PMI-led campaign to raise global awareness of our passion and determination to constantly improve and evolve, as well as highlight the power of science, technology and innovation to build a better future. PMI has partnered with Ducati Corse since 2002 and has extended the relationship for another three years until the end of 2021. As of the start of this year’s MotoGP season, the team will be officially known as Mission Winnow Ducati. Mission Winnow was first launched in October 2018 with Scuderia Ferrari Mission Winnow, which – like Ducati Corse – has a passion for innovation and a relentless drive to improve in the team’s pursuit of victory. Ducati Corse is one of the most inspiring and resilient teams in MotoGP, with a 70-year history in racing. Ducati fans form a passionate community who appreci
IFF’s Frutarom Division Completes Acquisition of 60% of Thailand-based Mighty18.1.2019 12:50 | Pressemelding
Regulatory News: International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris:IFF) (TASE:IFF), announced that its Frutarom Division has completed the acquisition of 60% of the share capital of The Mighty CO. LTD. (“Mighty”), a leading savory solutions provider in Thailand, thus continuing its growth strategy in Southeast Asia. Amos Anatot, President of IFF's Frutarom Division, said, “The completion of this deal with Mighty underscores that the Frutarom division will continue on its growth strategy and pursue attractive companies that create new opportunities or build on current capabilities.” Mr. Anatot continued, “And in this case, we are helping to grow our capabilities in savory solutions – already an area of strength for legacy Frutarom, now IFF." Mighty, founded in 1989, develops, produces and markets reaction flavors, with particular expertise in savory solutions. The company’s portfolio includes flavors, seasoning blends, marinades, and specialty functional raw materials f
LTI Q3 FY19: Constant currency revenue growth up 6.1% QoQ and 20.6% YoY; Net Profit jumps 32.8% YoY18.1.2019 12:02 | Pressemelding
Larsen & Toubro Infotech (BSE code: 540005, NSE: LTI), a global technology consulting and digital solutions company, announced its Q3 FY19 results today. In US Dollars: Revenue at USD 346.9 million; growth of 5.6% QoQ and 18.2% YoY Constant Currency Revenue growth of 6.1% QoQ and 20.6% YoY In Indian Rupees: Revenue at Rs 24,729 million; growth of 6.1% QoQ and 31.3% YoY Net Income at Rs 3,755 million; growth of (6.2%) QoQ and 32.8% YoY “We are pleased to deliver another strong quarter with 5.6% QoQ growth in USD revenues. Our broad-based revenue growth, superior margin delivery and steady cash generation in Q3 is a testimony of our focused execution and client centricity. We are also thrilled to welcome Ruletronics to LTI family. Ruletronics enables businesses to transform and evolve digitally by providing innovative BPM and CRM solutions leveraging Pega Platform.” - Sanjay Jalona, Chief Executive Officer & Managing Director, LTI Recent Deal Wins Nets, the leading payments company in th
Schlumberger Announces Full-Year and Fourth-Quarter 2018 Results18.1.2019 12:00 | Pressemelding
Schlumberger Limited (NYSE: SLB) today reported results for full-year 2018 and the fourth quarter of 2018. (Stated in millions, except per share amounts) Full-Year Results Twelve Months Ended Change Dec. 31, 2018 Dec. 31, 2017 Year-on-year Revenue $32,815 $30,440 8% Pretax operating income $4,187 $3,921 7% Pretax operating margin 12.8% 12.9% -12 bps Net income (loss) - GAAP basis $2,138 $(1,505) n/m Net income, excluding charges & credits* $2,261 $2,085 8% Diluted EPS (loss per share) - GAAP basis $1.53 $(1.08) n/m Diluted EPS, excluding charges and credits* $1.62 $1.50 8% Full-Year Consolidated Revenue by Area North America $11,984 $9,487 26% Latin America 3,745 3,976 -6% Europe/CIS/Africa 7,158 7,072 1% Middle East & Asia 9,543 9,394 2% Other 385 511 n/m $32,815 $30,440 8% North America revenue $11,984 $9,487 26% International revenue $20,446 $20,442 - North America revenue, excluding Cameron $9,668 $7,518 29% International revenue, excluding Cameron $17,675 $17,423 1% *These are non
FLIR Systems Awarded $89 Million Contract from French Armed Forces to Deliver Black Hornet Personal Reconnaissance System18.1.2019 11:00 | Pressemelding
FLIR Systems, Inc. (NASDAQ: FLIR) announced today it has been awarded a contract from the French Defense Procurement Agency (DGA) in support of the French Operational Pocket Drone (DrOP) program. The contract has a ceiling value of $89 million to provide the FLIR Black Hornet® 3 nano-unmanned aerial vehicle (UAV) and Personal Reconnaissance System (PRS) to support French Armed Forces operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190118005085/en/ The French Armed Forces awarded FLIR Systems a contract to deliver the Black Hornet Personal Reconnaissance System for military operations. (Photo: Business Wire) The Black Hornet PRS is the world’s smallest combat-proven nano-Unmanned Aerial System (UAS) and is currently deployed in more than 30 countries. The Black Hornet enables the warfighter to maintain situational awareness, threat detection, and surveillance no matter where the mission takes them. Equipped with el